Liquidia Technologies (NASDAQ:LQDA) issued its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.25, Bloomberg Earnings reports. Liquidia Technologies had a negative return on equity of 139.62% and a negative net margin of 1,964.76%. The business had revenue of $8.07 million for the quarter, compared to analyst estimates of $0.69 million.
NASDAQ LQDA traded down $0.21 on Friday, reaching $7.10. The company had a trading volume of 128,209 shares, compared to its average volume of 58,827. The company has a 50 day moving average of $7.70. The company has a market capitalization of $136.28 million and a PE ratio of -0.95. The company has a debt-to-equity ratio of 0.46, a quick ratio of 5.57 and a current ratio of 5.57. Liquidia Technologies has a 52 week low of $5.82 and a 52 week high of $38.46.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. OZ Management LP bought a new stake in Liquidia Technologies in the first quarter valued at about $1,138,000. Bank of New York Mellon Corp bought a new stake in Liquidia Technologies in the fourth quarter valued at about $403,000. FMR LLC increased its holdings in Liquidia Technologies by 3.2% in the fourth quarter. FMR LLC now owns 253,240 shares of the company’s stock valued at $5,485,000 after purchasing an additional 7,938 shares during the last quarter. Millennium Management LLC increased its holdings in Liquidia Technologies by 91.6% in the fourth quarter. Millennium Management LLC now owns 193,277 shares of the company’s stock valued at $4,186,000 after purchasing an additional 92,399 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Liquidia Technologies by 50.1% in the fourth quarter. Geode Capital Management LLC now owns 49,319 shares of the company’s stock valued at $1,068,000 after purchasing an additional 16,453 shares during the last quarter. Institutional investors and hedge funds own 56.37% of the company’s stock.
About Liquidia Technologies
Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension.
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.